Insulet Corporation vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Acton MA tubeless insulin pump (NASDAQ: PODD) $2.18B FY2024 revenue (+21%); Omnipod 5 automated insulin delivery with Dexcom/Libre integration, type 2 expansion, competing with Medtronic MiniMed and Tandem.
About
Insulet Corporation is an Acton, Massachusetts-based medical device company — publicly traded on the NASDAQ (NASDAQ: PODD) as an S&P 500 Health Care component — developing, manufacturing, and commercializing the Omnipod insulin delivery system: a tubeless, wearable, waterproof insulin pump patch worn directly on the body without tubing connections to a separate controller, automatically delivering insulin to people with type 1 and type 2 diabetes through approximately 5,000 employees globally. In fiscal year 2024, Insulet reported revenues of $2.18 billion (+21% year-over-year), driven by Omnipod 5 (Omnipod's automated insulin delivery — AID — system integrating with Dexcom CGM and Abbott FreeStyle Libre sensors to automatically adjust insulin delivery based on real-time glucose readings without manual user input), which drove international expansion in Europe and adoption in type 2 diabetes patients who previously used multiple daily injections rather than insulin pumps. CEO Jim Hollingshead has accelerated Omnipod's differentiation through the automated insulin delivery positioning: Omnipod 5's algorithm automatically modulates basal insulin rates every 5 minutes based on continuous glucose monitor readings — reducing A1c levels and time-in-hypoglycemia without requiring the user to manually program correction boluses for most scenarios — transforming diabetes management from active self-management to a background automated process that dramatically improves quality of life for insulin-dependent diabetics.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.